ONCOLYTICS director granted 96,000 stock options

ONCOLYTICS BIOTECH INC director Stephen C. Glover received a grant of 96,000 stock options.

Rhea-AI Filing Summary

ONCOLYTICS BIOTECH INC director Stephen C. Glover received a grant of 96,000 stock options. The options have an exercise price of $1.06 per share, equal to the Nasdaq closing price on June 1, 2026, and expire on June 1, 2036.

The options vest in three equal annual installments starting on June 1, 2027, contingent on Mr. Glover’s continued service or employment. This is a compensation-related award rather than an open-market purchase or sale of common shares.

Insider Trade Summary

Grant/Award: 96,000 shares

Grant/Award 1 txn

Insider Glover Stephen C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	96,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 96,000 contracts (Direct)

Footnotes (2)

1. F1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.
2. F2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

Key Figures

Options granted: 96,000 options Exercise price: $1.06 per share Underlying shares: 96,000 common shares +3 more

6 metrics

Options granted 96,000 options Stock option award to director Stephen C. Glover

Exercise price $1.06 per share Equal to Nasdaq closing price on June 1, 2026

Underlying shares 96,000 common shares Shares issuable upon exercise of options

Expiration date June 1, 2036 Option term end date

Vesting schedule 3 equal annual installments First tranche vests June 1, 2027

Shares after transaction 96,000 derivative securities Total stock options held following grant

Key Terms

Stock Option, exercise price, vests in three equal annual installments, Nasdaq Capital Market

4 terms

Stock Option financial

"security_title: Stock Option"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"The exercise price is equal to the closing price of the Issuer's common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in three equal annual installments financial

"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027"

Nasdaq Capital Market financial

"closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Stephen C. Glover acquire in the latest ONCY Form 4 filing?

Stephen C. Glover received a grant of 96,000 stock options in ONCOLYTICS BIOTECH INC. These options give him the right to buy common shares at a fixed exercise price as part of his compensation, rather than reflecting an open-market trade.

What is the exercise price of Stephen C. Glover’s ONCY stock options?

The exercise price of the granted options is $1.06 per share. This price equals the closing price of ONCOLYTICS BIOTECH INC common stock on the Nasdaq Capital Market on the grant date of June 1, 2026, according to the filing footnote.

How do Stephen C. Glover’s ONCY stock options vest over time?

The 96,000 stock options vest in three equal annual installments beginning June 1, 2027. Each year, one-third becomes exercisable, provided Mr. Glover continues his service or employment with ONCOLYTICS BIOTECH INC on each scheduled vesting date.

When do Stephen C. Glover’s ONCY stock options expire?

The granted stock options expire on June 1, 2036, giving a ten-year term from the grant date. After that expiration date, any unexercised options will lapse and can no longer be used to purchase ONCOLYTICS BIOTECH INC common shares.

Does the ONCY Form 4 show a market purchase or sale by Stephen C. Glover?

The Form 4 reports a grant of stock options, not a market purchase or sale. The transaction code “A” indicates a grant or award, which is a compensation event rather than an open-market trade of ONCOLYTICS BIOTECH INC common shares.

How many ONCY shares underlie Stephen C. Glover’s new stock options?

The options cover 96,000 underlying common shares of ONCOLYTICS BIOTECH INC. This means that, once vested and before expiration, Mr. Glover may choose to exercise the options to buy up to 96,000 shares at the fixed exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glover Stephen C.

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$1.06(1)	06/01/2026		A		96,000		(2)	06/01/2036	Common Shares	96,000	$0	96,000	D

Explanation of Responses:

1. The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.

2. The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.

	/s/ Kirk Look, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)